We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

In this video, I will go over Novo Nordisk's (NVO-1.22%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

He was 84. The director of more than 20 films, including “Xica da Silva” and “Bye Bye Brazil,” Diegues was a leading figure in Cinema Novo, a movement that emerged in the 1960s and used ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...